Moreover, many of the novel treatment strategies in allergic disorders (e.g., atopic dermatitis) and chronic respiratory diseases (severe eosinophilic asthma, EGPA, eosinophilic COPD, HES) specifically target eosinophils (i.e., mepolizumab/anti-IL-5 mAb or benralizumab/anti-IL-5R mAb) [26]. Here, IL5 is linked to hypereosinophilic syndrome.